GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (LTS:0NZU) » Definitions » EV-to-FCF

Zealand Pharma AS (LTS:0NZU) EV-to-FCF : -23.61 (As of Apr. 07, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zealand Pharma AS's Enterprise Value is kr22,288.62 Mil. Zealand Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-943.96 Mil. Therefore, Zealand Pharma AS's EV-to-FCF for today is -23.61.

The historical rank and industry rank for Zealand Pharma AS's EV-to-FCF or its related term are showing as below:

LTS:0NZU' s EV-to-FCF Range Over the Past 10 Years
Min: -111.49   Med: -12.2   Max: 80.57
Current: -23.61

During the past 13 years, the highest EV-to-FCF of Zealand Pharma AS was 80.57. The lowest was -111.49. And the median was -12.20.

LTS:0NZU's EV-to-FCF is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 2.335 vs LTS:0NZU: -23.61

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-07), Zealand Pharma AS's stock price is kr424.80. Zealand Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-16.270. Therefore, Zealand Pharma AS's PE Ratio (TTM) for today is At Loss.


Zealand Pharma AS EV-to-FCF Historical Data

The historical data trend for Zealand Pharma AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS EV-to-FCF Chart

Zealand Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.72 -4.56 -10.10 -45.11 -45.25

Zealand Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.11 -85.29 -101.80 -69.38 -45.25

Competitive Comparison of Zealand Pharma AS's EV-to-FCF

For the Biotechnology subindustry, Zealand Pharma AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's EV-to-FCF falls into.


;
;

Zealand Pharma AS EV-to-FCF Calculation

Zealand Pharma AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=22288.622/-943.964
=-23.61

Zealand Pharma AS's current Enterprise Value is kr22,288.62 Mil.
Zealand Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-943.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma AS  (LTS:0NZU) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Zealand Pharma AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=424.80/-16.270
=At Loss

Zealand Pharma AS's share price for today is kr424.80.
Zealand Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.270.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Zealand Pharma AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines